# Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

Study · id `cardio:ct-nct02604264` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02604264](<https://clinicaltrials.gov/study/NCT02604264>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02604264

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2912 participants.

## Technical summary

Registry record NCT02604264. Randomized; no masking; primary purpose treatment. Start 2014-12 (actual); primary completion 2015-11 (actual). Results posted on 2017-05-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2912 participants (enrolled count; ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Started: 2014-12 (actual) (ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Primary completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Results first posted: 2017-05-01 (ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02604264, source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02604264-2018-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
- Condition: End Stage Renal Disease (ESRD)
- Intervention (Device): ClearGuard HD end cap
- Lead sponsor: Pursuit Vascular, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Fresenius Medical Care North America
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap (`cardio:pubmed-27839894`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eeaed44429b674f2edae4215f8bd033b2eb526ce917e8b7391a6c10576ae793f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
